Cart
sales@molnova.com
Home -
Products -
Others -
Other Targets -
APL1β27 trifluoroacetate salt/APLP1-derived Aβ-like peptide (1-27)
APL1β27 trifluoroacetate salt/APLP1-derived Aβ-like peptide (1-27)
CAS No. 1233876-44-2
APL1β27 trifluoroacetate salt/APLP1-derived Aβ-like peptide (1-27)( ——— )
Catalog No. M40886 CAS No. 1233876-44-2
APL1β27 trifluoroacetate salt/APLP1-derived Aβ-like peptide (1-27)
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | Get Quote | Get Quote |
|
| 50MG | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAPL1β27 trifluoroacetate salt/APLP1-derived Aβ-like peptide (1-27)
-
NoteResearch use only, not for human use.
-
Brief DescriptionAPL1β27 trifluoroacetate salt/APLP1-derived Aβ-like peptide (1-27)
-
DescriptionAPL1β27 trifluoroacetate salt/APLP1-derived Aβ-like peptide (1-27)
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number1233876-44-2
-
Formula Weight2472.76
-
Molecular FormulaC103H174N30O38S1
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Melperone
Melperone a butyrophenone tranquillizer caused bradycardia in vivo and in vitro.
-
Norchelerythrine
Norchelerythrine shows significant inhibitory activity against Staphylococcus aureus ATCC 6538 with MIC values ranging from 12.5 to 50 ug/mL. It exhibits strong antifeeding activity in a concentration-dependant manner with the EC50 of 62.67 ppm.
-
Examorelin
Examorelin is an agonist of growth hormone-releasing factor (GHRF), and for the treatment of cardiac diseases.hexarelin treatment protected cardiac function in the chronic phase as evidenced by higher ejection fraction and fractional shortening, as well as lower lung weight/body weight and lung weight/tibial length ratios, compared with vehicle treatment.?
